专业监测看板

Determining the Effects of Temozolomide Followed by Nivolumab in Patients With Colorectal Cancer

药物 / 成分：TMZ、Nivolumab

登记的停止原因（原文）：No accrual

Frespaciguat (MK-5475) in Participants With Hypoxemia Due to COVID-19 Pneumonia (MK-5475-009)

药物 / 成分：Frespaciguat、Placebo

登记的停止原因（原文）：Business reasons

Selective PDE9 Inhibition With IMR-687 in Adults With Heart Failure With Preserved Ejection Fraction

药物 / 成分：IMR-687、IMR-687 Placebo

登记的停止原因（原文）：Study Termination

A Phase 3 Study Evaluating the Safety and Efficacy of Denifanstat in Patients With MASH and F2/F3 Fibrosis

药物 / 成分：Denifanstat、Placebo

登记的停止原因（原文）：Business decision

A Phase 3 Study Evaluating the Safety and Efficacy of Denifanstat in Patients With MASLD and MASH

药物 / 成分：denifanstat、Placebo

登记的停止原因（原文）：Business decision

Systemic Absorption of Dexamethasone Oral Rinse in Patients With Oral Lichen Planus

药物 / 成分：dexamethasone oral rinse

登记的停止原因（原文）：Study protocol changed to be a retrospective exempt review project.

Birinapant and Carboplatin in Treating Patients and Targeting Recurrent High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (HGSOC)

药物 / 成分：Birinapant、Carboplatin、Laboratory Biomarker Analysis、Pharmacological Study

登记的停止原因（原文）：funding was not secured

A Phase I Trial of Donor- Derived 19-28z CAR T Cells Following Allogeneic Transplant for the Treatment of CD19 Malignancies

药物 / 成分：CAR T-Cell Infusion

登记的停止原因（原文）：No patients were enrolled to this study since being open to enrollment. Due to changes in available therapies, there aren't enough people who will be eligible for the study. Therefore, the study was closed.

OLP to Manage Pain in TJA: A Feasibility Study

药物 / 成分：Open Label Placebo、Patient medication as standardly prescribed

登记的停止原因（原文）：Study was never initiated.

PET and MRI Imaging With Scopolamine at the Muscarinic M1 Receptor

药物 / 成分：Scopolamine、[11C]EMO ([11C]LSN3172176)

登记的停止原因（原文）：lack of enrollment

Study to Compare the Efficacy, Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of MAB-22 Versus Prolia®

药物 / 成分：MAB-22、Prolia®

登记的停止原因（原文）：Business decision not to proceed with the study.

Enhancing Recovery Through a Combined Mechanobiologic Intervention Following Meniscus Repair

药物 / 成分：Fisetin、Placebo oral capsule

登记的停止原因（原文）：Funding not awarded

Double-blind Trial of Sodium Thiosulfate for the Treatment of Pain Associated With Calcific Uremic Arteriolopathy

药物 / 成分：Sodium thiosulfate、Placebo

登记的停止原因（原文）：Company decision -terminated on 30 October 2015

Immunotherapy Before Transplantation for Skin Cancer Prevention in Organ Transplant Recipients

药物 / 成分：Calcipotriol Only Product in Cutaneous Dose Form、Vaseline、Topical 5FU

登记的停止原因（原文）：The study was withdrawn due to lack of financial support.

S-Nitrosylation Therapy of COVID-19

药物 / 成分：SNO、Nitrogen gas

登记的停止原因（原文）：Study delays

Immunotherapy After Transplantation for Skin Cancer Prevention in Organ Transplant Recipients

药物 / 成分：Calcipotriol Only Product in Cutaneous Dose Form、Vaseline、Topical 5FU

登记的停止原因（原文）：The study was withdrawn due to lack of financial support.

A Multi-center Evaluation of Aldafermin in a Randomized, Double-blind, Placebo-controlled Study in Subjects With Primary Sclerosing Cholangitis.

药物 / 成分：aldafermin、Placebo

登记的停止原因（原文）：Study was terminated by the Sponsor because the FDA advised a trial design change which made it infeasible to continue the study.

Rituximab Treatment of Focal Segmental Glomerulosclerosis

药物 / 成分：rituximab

登记的停止原因（原文）：Problems with drug supply

PD-1, LAG-3 and TIM-3 Checkpoint Blockade in DLBCL

药物 / 成分：Retifanlimab, INCAGN02385, INCAGN02390

登记的停止原因（原文）：Investigator request to no longer pursue this study. Lack of support from drug company. This trial never opened. Withdrew IND.

Investigational Drug in Combination With Two Chemotherapy Drugs in Women With Locally Recurrent or Metastatic Breast Cancer

药物 / 成分：Ixabepilone、Capecitabine、Motesanib